LXRX
Income statement / Annual
Last year (2023), Lexicon Pharmaceuticals, Inc.'s total revenue was $1.20 M,
an increase of 766.19% from the previous year.
In 2023, Lexicon Pharmaceuticals, Inc.'s net income was -$177.12 M.
See Lexicon Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.20 M
|
$139,000.00
|
$298,000.00
|
$24.00 M
|
$322.07 M
|
$63.21 M
|
$90.34 M
|
$83.34 M
|
$130.01 M
|
$22.85 M
|
| Cost of Revenue |
$85,000.00 |
$427,000.00 |
$55.05 M |
$1.93 M |
$3.23 M |
$2.49 M |
$1.90 M |
$163.97 M |
$95.19 M |
$89.28 M |
| Gross Profit |
$1.12 M |
-$288,000.00 |
-$54.75 M |
$22.07 M |
$318.84 M |
$60.72 M |
$88.44 M |
-$80.64 M |
$34.83 M |
-$66.43 M |
| Gross Profit Ratio |
0.93 |
-2.07 |
-183.72 |
0.92 |
0.99 |
0.96 |
0.98 |
-0.97 |
0.27 |
-2.91 |
| Research and Development
Expenses |
$58.89 M
|
$52.82 M
|
$55.05 M
|
$153.62 M
|
$91.92 M
|
$100.24 M
|
$156.81 M
|
$178.15 M
|
$95.19 M
|
$89.28 M
|
| General & Administrative
Expenses |
$0.00
|
$48.08 M
|
$0.00
|
$0.00
|
$0.00
|
$63.75 M
|
$66.20 M
|
$43.04 M
|
$23.84 M
|
$19.41 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$113.98 M
|
$48.08 M
|
$32.34 M
|
$47.23 M
|
$56.84 M
|
$63.75 M
|
$66.20 M
|
$43.04 M
|
$23.84 M
|
$19.41 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$1.60 M |
$28.64 M |
$0.00 |
$1.95 M |
$2.29 M |
$572,000.00 |
$2.26 M |
| Operating Expenses |
$172.87 M |
$100.90 M |
$87.39 M |
$200.85 M |
$148.76 M |
$164.00 M |
$223.02 M |
$221.20 M |
$119.02 M |
$108.69 M |
| Cost And Expenses |
$172.95 M |
$100.90 M |
$87.39 M |
$202.78 M |
$151.99 M |
$166.49 M |
$224.92 M |
$221.20 M |
$119.02 M |
$108.69 M |
| Interest Income |
$7.73 M |
$1.60 M |
$134,000.00 |
$2.77 M |
$3.35 M |
$3.51 M |
$1.95 M |
$2.29 M |
$572,000.00 |
$2.26 M |
| Interest Expense |
$13.10 M |
$2.78 M |
$802,000.00 |
$14.54 M |
$20.68 M |
$20.78 M |
$6.98 M |
$6.57 M |
$6.72 M |
$2.25 M |
| Depreciation &
Amortization |
$554,000.00
|
$427,000.00
|
$292,000.00
|
$2.93 M
|
$3.65 M
|
$3.68 M
|
$3.40 M
|
$2.06 M
|
$727,000.00
|
$1.93 M
|
| EBITDA |
-$163.46 M
|
-$98.74 M
|
-$86.66 M
|
-$41.10 M
|
$173.74 M
|
-$96.09 M
|
-$125.27 M
|
-$125.82 M
|
$11.72 M
|
-$96.18 M
|
| EBITDA Ratio |
-135.77 |
-713.41 |
-291.8 |
-7.34 |
0.54 |
-1.58 |
-1.47 |
-1.63 |
0.09 |
-3.66 |
| Operating Income Ratio
|
-142.65
|
-724.89
|
-292.25
|
-7.45
|
0.44
|
-1.63
|
-1.51
|
-1.65
|
0.01
|
-4.39
|
| Total Other
Income/Expenses Net |
-$5.37 M
|
-$1.18 M
|
-$668,000.00
|
-$10.77 M
|
-$17.33 M
|
-$17.27 M
|
-$5.03 M
|
-$4.27 M
|
-$6.15 M
|
$2,000.00
|
| Income Before Tax |
-$177.12 M |
-$101.94 M |
-$87.76 M |
-$58.57 M |
$124.12 M |
-$120.55 M |
-$141.71 M |
-$141.43 M |
-$4.68 M |
-$100.36 M |
| Income Before Tax Ratio
|
-147.11
|
-733.41
|
-294.49
|
-2.44
|
0.39
|
-1.91
|
-1.57
|
-1.7
|
-0.04
|
-4.39
|
| Income Tax Expense |
$0.00 |
$1.18 M |
$510,000.00 |
$11.61 M |
-$6.01 M |
$3.51 M |
-$12.66 M |
$4.51 M |
$6.00 M |
-$70,000.00 |
| Net Income |
-$177.12 M |
-$103.13 M |
-$88.27 M |
-$70.18 M |
$130.13 M |
-$120.55 M |
-$129.05 M |
-$141.43 M |
-$4.68 M |
-$100.29 M |
| Net Income Ratio |
-147.11 |
-741.93 |
-296.2 |
-2.92 |
0.4 |
-1.91 |
-1.43 |
-1.7 |
-0.04 |
-4.39 |
| EPS |
-0.8 |
-0.62 |
-0.61 |
-0.63 |
1.23 |
-1.14 |
-1.23 |
-1.36 |
-0.0452 |
-1.31 |
| EPS Diluted |
-0.8 |
-0.62 |
-0.61 |
-0.63 |
1.11 |
-1.14 |
-1.23 |
-1.36 |
-0.0452 |
-1.31 |
| Weighted Average Shares
Out |
$221.13 M
|
$165.73 M
|
$145.65 M
|
$110.84 M
|
$106.22 M
|
$105.74 M
|
$105.12 M
|
$103.86 M
|
$103.59 M
|
$76.35 M
|
| Weighted Average Shares
Out Diluted |
$221.13 M
|
$165.73 M
|
$145.65 M
|
$110.84 M
|
$116.75 M
|
$105.83 M
|
$105.24 M
|
$103.86 M
|
$103.59 M
|
$76.35 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
